Though serum iron has been known to be associated with an increased risk of infection, hepcidin, the major regulator of iron metabolism, has never been systematically explored in this setting. Finding early biomarkers of infection, such as hepcidin, could help identify patients in whom early empiric antimicrobial therapy would be beneficial. We prospectively enrolled consecutive patients (n 5 128) undergoing first-time, single-organ orthotopic liver transplantation (OLT) without known iron overload disorders at 2 academic hospitals in Boston from August 2009 to November 2012. Cox regression compared the associations between different iron markers and the development of first infection at least 1 week after OLT; 47 (37%) patients developed a primary outcome of infection at least 1 week after OLT and 1 patient died. After adjusting for perioperative bleeding complications, number of hospital days, and hepatic artery thrombosis, changes in iron markers were associated with the development of infection post-OLT including increasing ferritin (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.12-2.05), rising ferritin slope (HR, 1.10; 95% CI, 1.03-1.17), and increasing hepcidin (HR, 1.43; 95% CI, 1.05-1.93). A decreasing iron (HR, 1.76; 95% CI, 1.20-2.57) and a decreasing iron slope (HR, 4.21; 95% CI, 2.51-7.06) were also associated with subsequent infections. In conclusion, hepcidin and other serum iron markers and their slope patterns or their combination are associated with infection in vulnerable patient populations.
including orthotopic liver transplantation (OLT) recipients. New biomarkers for infection in high-risk populations could facilitate targeted preventative or early treatment strategies leading to improved prognosis and outcomes. Increased levels of tissue and serum iron have been associated with invasive infections in OLT recipients.
(1-3) Serum iron markers could serve as early predictive biomarkers for infection in this vulnerable patient population.
Multiple in vitro studies and animal models have demonstrated that iron promotes increased virulence of bacterial and fungal pathogens by counteracting the innate antimicrobial effects of host plasma. (4, 5) Iron may become available as nutrition for microorganisms from multiple intracellular and extracellular sources. (6) (7) (8) (9) Readily available plasma iron is metabolized by pathogens, facilitating increased bacterial and fungal growth which may overwhelm other host defenses and result in clinical infection. Host iron sequestration reverses this pathogenic effect and restores the antimicrobial properties of host serum. (10) Furthermore, acute events, such as infection, trauma, and surgery, lead to rapid drops in serum iron, or "stress hypoferremia," and increased iron storage. (11, 12) This decrease in iron availability, or iron-withholding from host serum, may serve as a defense mechanism after infection or other stressful events and is referred to as "nutritional immunity." (13) Hepcidin, the master regulator hormone of systemic extracellular iron homeostasis, is an acute phase peptide predominantly produced by hepatocytes. (14) Hepcidin synthesis is induced by infection and inflammation, and, independently, by iron loading or iron stores. (15) (16) (17) Conversely, hepcidin production is suppressed by anemia, hypoxia, and active erythropoiesis. (18, 19) Hepcidin acts to decrease duodenal enterocyte dietary iron absorption, decrease iron efflux from macrophages that recycle iron from senescent erythrocytes, and decrease iron efflux from hepatocytes that store iron. (17) These hepcidin-mediated mechanisms of iron sequestration reduce serum iron levels thereby reducing the amount of iron available to extracellular pathogens.
Since the discovery of hepcidin, much progress has been made in understanding the molecular basis of iron metabolism; however, the study of hepcidin in the clinical setting remains limited. Hepcidin has never been systematically and prospectively studied in an OLT population as a predictor for infection. Studies to date examining iron and infection in solid organ transplant recipients were retrospective and used banked specimens to quantify iron. (1) (2) (3) 20, 21) The purpose of this hypothesis-generating study is to begin exploring the host-pathogen relationship between iron metabolism and infection in a post-OLT population.
Patients and Methods

PATIENT POPULATION
Consecutive adults undergoing OLT at Tufts Medical Center and Lahey Medical Center in Boston, MA were enrolled from August 2009 until November 2012 after giving written informed consent. Exclusion criteria included dual organ transplant recipients, retransplantation of the liver, and any known preexisting conditions predisposing to iron overload (eg, hemochromatosis). Patients were followed for 6 months after OLT as inpatients and outpatients. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional review boards at each institution.
CLINICAL DATA
Data collected included demographics, donor characteristics, intraoperative and postoperative transfusions, operative complications, immunosuppressant and antimicrobial treatments, supplemental nutrition, and routine laboratory data. Patients were initially on a corticosteroid taper, mycophenolate mofetil (MMF), and tacrolimus. The immunosuppression protocols did not differ by center, donor type, or hepatitis C virus (HCV) infection status. Valganciclovir was used for cytomegalovirus (CMV) prophylaxis for 6 months for those at highest risk (donor [D]1/recipient [R]-) and for 3 months in all others.
BLOOD SAMPLE COLLECTION AND IRON MARKER MEASUREMENTS
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Additional supporting information may be found in the online version of this article. microbiological cultures, or ordering of empiric antimicrobial therapy. Hepcidin was measured by a validated competitive enzyme-linked immunosorbent assay (22) and iron, ferritin, and C-reactive protein (CRP) were measured by standard clinical laboratory assays.
OUTCOME DEFINITIONS
Our primary outcome was time to first infection at least 1 week after OLT. Definite infection was defined as microbiological, histologic, or pathologic isolation of an organism from a normally sterile site with clinical signs and symptoms of infection. (23) (24) (25) Possible infection was defined as clinical signs and symptoms of infection warranting treatment with empiric antibiotics per infectious disease physician with no evidence of a positive microbiology, histology, or pathology test. All potential infections were adjudicated by a panel of 3 transplant infectious disease physicians who were blinded to iron measurements. Nosocomial infections were classified using Centers for Disease Control definitions. (26) The date from which the positive culture or tissue pathology sample was taken or the date during which a triggered blood sample was collected for suspected infection per the above criteria was defined as the date of infection.
STATISTICAL ANALYSES
Baseline patient characteristics were summarized for those with definite or possible infection and those without infection. Because hepcidin is not induced in acute HCV infection, patients with HCV re-activation alone were classified as noninfected for all analyses. (27) Univariate survival analysis was performed on both baseline and time-dependent covariates to determine which variables were associated with development of a first infection using Cox proportional hazards models.
Boxplots of iron parameters were compared with those who developed a first definite infection at least 1 week after OLT, and those who never developed an infection. Patients with possible infections were excluded. For patients who did not develop an infection, the levels of iron parameters were matched to each infection date at the same number of days after OLT 62 days and also were matched to each infection date 130 days. The noninfected patients were resampled to calculate the corresponding "noninfected" iron parameter medians for each matched date. Given that longitudinal patterns of iron markers over time have not previously been characterized in relationship to infections, multiple continuous iron marker metrics were explored to develop statistically and clinically meaningful models. Examples of raw and derived iron variables for modeling are shown in Supporting Table 1 .
Multivariate Cox proportional hazards models were used to examine the relationship between iron markers and time to first infection at least 1 week after OLT. Covariates thought a priori to be of clinical importance and those with univariate statistical significance at P < 0.20 were used as candidate variables for possible inclusion in multivariate model building. To avoid overfitting the models, they were restricted to 3 covariates using best subsets selection methods. The proportional hazards assumption of each model was assessed using a method based on weighted Schoenfeld residuals. (28) All statistics were performed using SAS, version 9.4 (SAS Institute, Cary, NC).
SENSITIVITY ANALYSES
Clinically meaningful subgroups were selected a priori for comparison, including those with and without HCV infection, those with and without hepatocellular carcinoma, and those with living versus deceased liver donors. In addition, different definitions of infection were used as sensitivity analyses including the following: definite infections as the outcome with possible infections reclassified as not infected, or with possible infections excluded from analysis, or with possible infections censored on the date of possible infection.
We decided, a priori, to test clinically important interactions between transfusion products, heparin, and iron markers. (29) In addition, because of the high variability seen during the initial period of posttransplant recovery, we performed another sensitivity analysis that excluded data from the first week after OLT.
Results
PATIENT POPULATION
A total of 130 patients were enrolled in the study (Fig.  1) . One patient died within 3 weeks, and 1 patient was retransplanted within 7 days. Both were excluded due to lack of blood samples and neither had developed an infection, yielding 128 patients who were analyzed. The majority of study patients were white males (Table  1) and underwent transplantation for either HCV or alcoholic liver disease. Almost half of the patients also had hepatocellular carcinoma. Notably, one-third of our study patients received organs from living donors. Most received red blood cell (RBC) transfusions with more transfusions given to patients in the group that developed infections. The infected group also more often underwent complex transplant operations, had more posttransplant surgical complications, and had longer hospital stays. The mean tacrolimus trough did not differ significantly between those with and without infection. MMF was tapered off by 3 months after OLT in 60% of patients. Immunosuppression did not differ by HCV status or by donor type (data not shown).
INFECTIOUS OUTCOMES
There were a total of 67 patients with at least 1 infection ( Fig. 1) . We classified patients who only had recurrent HCV as noninfected (n 5 10). (27) In order to avoid including peritransplant infections, infectious episodes occurring within the first week after OLT were excluded, however, subsequent infections were analyzed as infectious outcomes. For our primary endpoint of time to first infection at least 1 week after OLT, there were a total of 47 infections that met inclusion criteria, three-quarters of which were definite and one-quarter of which were possible. The median The most common type of infection was intra-abdominal, which included cholangitis, intraabdominal abscesses, and peritonitis, and was followed by bloodstream infections. The most common organism isolated was Enterococcus spp. (Table 2) . Among analyzed patients, 1 patient with infection died, and none of the noninfected patients died during the study period.
IRON MARKERS
An average of 13 blood samples per patient were available for analysis of iron markers. When distributions of iron markers were compared, the median hepcidin was significantly higher at time of definite infection (200 ng/mL; IQR, 113-269 ng/mL; P 0.001) when compared with those who did not develop infection (102 ng/mL; IQR, 78-113 ng/mL; Fig. 2A ). At baseline and 30 days after infection, there was no significant difference in hepcidin between those who did and did not develop infection (Fig. 2B,C) . The median ferritin patterns were similar to those of hepcidin with a higher median ferritin at the time of definite infection (518 ng/mL; IQR, 320-824 ng/mL; P 5 0.003) when compared with those who did not develop infection (350 ng/mL; IQR, 184-495 ng/mL), and no significant differences were found at baseline or at 30 days after infection (Supporting Fig. 1 ). In contrast, the median iron was lower at the time of definite infection (43 lg/dL; IQR, 17-74 lg/dL; P 5 0.05) when compared with those who did not develop infection (62 lg/dL; IQR, 51-70 lg/dL; Supporting Fig. 2 ). Some general patterns in iron markers were observed. Immediately after OLT, ferritin would usually fall faster than hepcidin while iron increased during the first 30-45 days after OLT before all iron markers reached a relatively steady state (Fig. 3A) . In general, before an infection was diagnosed, hepcidin would rise first, followed by a rise in ferritin and a decrease in iron (Fig. 3B) . Intra-abdominal infection (n 5 6) Enterococcus species (n 5 6) CoNS (n 5 1) Polymicrobial (n 5 3) Unknown (n 5 3) Bloodstream infection (n 5 11) Pneumonia (n 5 2) Enterococcus species (n 5 4) CoNS (n 5 4) Gram-negative rod (n 5 3) Clostridum difficile colitis (n 5 3)
Surgical site infection (n 5 2) Skin and soft tissue infection (n 5 3) Other Polymicrobial (n 5 1)
Herpes Zoster (n 5 1) Unknown (n 5 2) Tracheobronchitis (n 5 1) Urinary tract infection (n 5 2) ESBL gram-negative rod (n 5 2) CMV infection (n 5 1) Candida esophagitis (n 5 1) Surgical site infection, unknown (n 5 1)
UNIVARIATE ASSOCIATIONS OF NONIRON COVARIATES WITH INFECTION
The associations between clinically important, noniron marker risk factors and infectious outcomes using univariate survival analysis are shown in Table 2 . Comparing types of underlying liver disease, HCV was associated with a decreased risk of infection after OLT. When examining time-dependent variables, hospital length of stay, the number of days receiving RBC transfusions or tube feeds, and number of hospital re-admissions were associated with an increased risk for infection. Several surgical complications were also associated with increased infections including 2-staged liver transplant procedures, bile leaks, bleeding, and hepatic artery thrombosis. In terms of laboratory values, decreasing albumin, increasing white blood count (WBC), and increasing CRP were associated with increased infections. Donor type, baseline iron markers, and baseline CRP were not associated with infectious risk. Transferrin saturation and total ironbinding capacity did not demonstrate as strong a relationship with infection (data not shown) compared with iron, ferritin, and hepcidin. In addition, no relationship was found between liver explant qualitative iron content and subsequent infectious events (hazard ratio [HR], 1.51; 95% confidence interval [CI], 0.83-2.73; P 5 0.18).
MULTIVARIABLE IRON MODELS
Many different iron metrics were found to be associated with infection on multivariate analyses; however, the focus here will be on the most easily clinically interpretable, statistically significant metrics (Table 3) . To facilitate interpretation of the HRs, iron variables were modeled to be associated with an increased risk of infection (Supporting Table 2 ). An increase in the ferritin slope and in ferritin were independently associated with an increased risk of infection after OLT after adjusting for hospital length of stay, bleeding complications, and hepatic artery thrombosis. Increases in hepcidin also were associated with increased infections. In contrast, decreases in iron slope and in iron were associated with an increased risk of infection. CRP, an acute phase reactant, and iron markers were correlated with each other (correlation coefficients ranged between 0.1 and 0.5) and with the infection outcomes. They were not independent predictors of infection when modeled together (data not shown). HCV status did not have an independent effect on iron markers. WBC and albumin (as a crude marker for liver synthetic function) also did not change the results of the multivariate models (Supporting Table 3 ).
SUBGROUP AND SENSITIVITY ANALYSES
The multivariate models for the different iron parameters were analyzed using subgroups including those with and without HCV, those with and without hepatocellular carcinoma, and those with living versus deceased liver donors. Results were similar for all iron markers and for all subgroups (Supporting Table 3 ). Sensitivity analyses were also performed using different definitions of infectious outcomes and yielded similar results (Supporting Table 3 ). We also tested for clinically important interactions between iron markers and donor type, iron markers and different types of transfusions, and iron markers and heparin. However, no 
Discussion
This is the first prospective longitudinal study of iron parameters, including hepcidin, and their association with infection in OLT. We found several different serum iron marker patterns to be associated with infection in OLT recipients. Increases in hepcidin and ferritin and decreases in iron were associated with an increased risk of infection after adjustment for other known risk factors for infection. The models accounted for the complexity of the post-OLT course by analyzing recognized risk factors for infection, such as surgical complications and blood product transfusions. Furthermore, the relationship between iron markers and infection remained similar in all of our sensitivity, subgroup, and interaction analyses. Our findings confirm retrospective studies where iron and infection relationships were previously found in immunocompromised patient populations (1) (2) (3) 21, 31, 32) and support the hypothesis that iron markers could serve as predictors for infection. The biology of iron metabolism provides a plausible pathophysiologic basis for a clinically meaningful relationship between iron and infection. By beginning to explore how iron markers behave in the setting of clinical infection, this sets the stage for future investigations of iron markers measured at standardized time points to determine diagnostic cutoffs, such as positive predictive and negative predictive values. Changes in serum hepcidin corresponded to opposite changes in serum iron, supporting the interpretation that hepcidin was driving the changes in serum iron and not vice versa. (17) Thus, increases in hepcidin coincided with decreases in serum iron, and both of these patterns were associated with an increased risk of infection. With resolving infection, serum hepcidin and ferritin decreased and the serum iron increased. Lowering extracellular iron is hypothesized to be a general defense mechanism against infection by withholding iron from various pathogens according to the concept of "nutritional immunity." (13) In an animal model, the protective effect of hypoferremia was shown when hepcidin-deficient mice infected with Vibrio vulnificus became septic and could be saved from sepsis by administration of a hepcidin agonist. (33) When hepcidin and iron inversely correlate, hepcidin synthesis is being primarily driven by infection and inflammation leading to hypoferremia. This decrease in iron feeds back to decrease hepcidin levels, thus blunting the hepcidin signal over time. This negative feedback hepcidin regulation loop could explain why hepcidin was not as strong a predictor for infection when compared with iron and ferritin. (34) Although our study suggests that iron markers and their slope patterns or their combination could serve as potential early biomarkers for infection, they may not be accurate predictors of acute or chronic HCV infections. Armitage et al. found no correlation between hepcidin or iron and acute hepatitis B or acute HCV infection (initial viremic phase) but did find an increase in hepcidin and a decrease in iron with acute human immunodeficiency virus (HIV) infection. (27) Our findings found a similar lack of relationship between HCV status and iron markers. Patients with recurrent HCV infection alone were therefore classified in our study as not infected. (27) In addition, hepcidin synthesis is suppressed in patients with chronic HCV infection. (35, 36) Limitations to our study include the small numbers of viral or fungal infections preventing our ability to draw any specific conclusions about these types of infections. Our cohort also had a larger percentage of living liver donors compared with most other liver transplant centers, which could limit generalizability of our results. There were also small numbers of those with hepatic artery thrombosis, which also could limit generalizability. However, we felt it was important to control for this covariate in the final multivariate models based on clinical considerations. There was only 1 death observed during the study period in a patient with infection, and perhaps our results would have been more dramatic in a sicker patient population. Also, due to limited blood sampling, we cannot accurately determine the exact hourly or daily time-course of rise in hepcidin and ferritin and decrease in iron in all cases. We also did not collect the pre-OLT baseline iron markers in serum or in native livers and could not confirm the association between baseline iron status and infections found in previous studies. (1, 2, 21) Finally, there could have been some imprecision in the "day of diagnosis" of an infectious episode, because it was based on clinical factors. However, this reflects the reality of clinical practice.
Future studies to determine the numeric parameters at which iron markers best serve as early predictors for infection could inform when cultures should be obtained or empiric antimicrobial therapy should be started. Also, a better definition of which patient populations would most benefit from using iron-related biomarkers for earlier detection or prediction of infection would be helpful. With further study, hepcidin agonists could also potentially be administered for therapeutic purposes to humans with infections. In experimental animal models of infection with Klebsiella pneumonia, iron-loaded hepcidin knockout mice were highly susceptible to infection and had higher mortality compared with wild-type mice. When treated with hepcidin analogues, which lowered serum iron concentrations, mortality was prevented or decreased among infected iron-loaded hepcidin knockout mice. The protective effect of hepcidin was caused by the restriction of available serum iron. These animal models support that hepcidin plays a role in innate immunity. (37, 38) Further exploration of hepcidinmediated iron sequestration in human host defense could lead to using hepcidin as an anti-infective therapeutic to supplement antimicrobials in immunosuppressed hosts.
In conclusion, in this prospective longitudinal study, we observed a relationship between serum iron markers and the subsequent development of infection in a cohort of liver transplant recipients after adjusting for potential confounders and known risk factors of infection. Time-dependent associations showed that increasing ferritin, ferritin slope, and hepcidin, as well as decreasing iron and iron slope were associated with the development of infection after OLT. The recognized risk factors for infection of length of hospital stay, bleeding complications, and hepatic artery thrombosis were verified. (39) (40) (41) (42) (43) (44) (45) Our study also supports the hypothesis that acute hypoferremia is a nearly universal host defense mechanism activated across the spectrum of infections, including in immunocompromised hosts. Our results make a case for further exploration of the use of hepcidin and other iron-related parameters as potential early biomarkers of infections in vulnerable patient populations. We hope this study generates ideas for future applications where manipulation of the iron metabolism pathway could be a potential therapeutic target for infection intervention.
